PE20040187A1 - Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo - Google Patents

Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Info

Publication number
PE20040187A1
PE20040187A1 PE2003000109A PE2003000109A PE20040187A1 PE 20040187 A1 PE20040187 A1 PE 20040187A1 PE 2003000109 A PE2003000109 A PE 2003000109A PE 2003000109 A PE2003000109 A PE 2003000109A PE 20040187 A1 PE20040187 A1 PE 20040187A1
Authority
PE
Peru
Prior art keywords
dispersion
inhibitor
phenyl
cetp
forming
Prior art date
Application number
PE2003000109A
Other languages
English (en)
Inventor
Marshall David Crew
William John Curatolo
Dwayne Thomas Friesen
Ravi Mysore Shanker
Douglas Alan Lorenz
James Alan Schriver Nightingale
Roger Benjamin Ruggeri
Michael Jon Gumkowski
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20040187A1 publication Critical patent/PE20040187A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A PROCEDIMIENTOS PARA FORMAR COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UNA DISPERSION AMORFA SOLIDA DE UN INHIBIDOR DE LA PROTEINA DE TRANSFERENCIA DE ESTERES DE COLESTERILO (CETP) Y UN POLIMERO QUE AUMENTA LA CONCENTRACION, MEDIANTE: a) POR UN PROCESADO EN DISOLVENTE,QUE CONSISTE EN FORMAR UNA SOLUCION QUE COMPRENDE UN INHIBIDOR DE CETP Y UN POLIMERO, EN UN DISOLVENTE COMUN PARA LUEGO ELIMINAR RAPIDAMENTE EL DISOLVENTE DE LA SOLUCION FORMANDO ASI LA DISPERSION, b) POR EXTRUSION EN ESTADO FUNDIDO, CONSISTE EN ALIMENTAR A UNA EXTRUSORA UN INHIBIDOR Y EL POLIMERO AMBOS SE EXTRUSIONA Y LUEGO SE SOLIDIFICAN FORMANDOSE UNA DISPERSION, c) POR CONGELACION EN ESTADO FUNDIDO, SE FORMA UNA MEZCLA FUNDIDA QUE COMPRENDE EL INHIBIDOR Y EL POLIMERO, LA MEZCLA SE ENFRIA FORMANDOSE LA DISPERSION. ENTRE LOS INHIBIDORES DE CETP SON PREFERIDOS: (4'S)-5'-(4-FLUOROFENIL)-6'-[(S)-FLUORO[4-(TRIFLUOROMETIL)FENIL]METIL]-3',4'-DIHIDRO-7'-(1-METILETIL)-ESPIRO[CICLOBUTANO-1,2'(1'H)-NAFTALEN]-4'-OL, (2R)-3-[[3-(4-CLORO-3-ETILFENOXI)FENIL][3-(1,1,2,2-TETRAFLUOROETOXI)FENIL]METIL]AMINO]-1,1,1-TRIFLUORO-2-PROPANOLOL, ENTRE OTROS. Y ENTRE LOS POLIMEROS SON SELECCIONADOS: CARBOXIMETILCELULOSA, COPOLIMERO POLIOXIETILENO-POLIOXIPROPILENO, ENTRE OTROS.ESTAS COMPOSICIONES PROPORCIONAN MEJORAS EN LA SOLUBILIDAD DE LOS INHIBIDORES CETP, PERMITIENDO REDUCIR LA DOSIFICACION REQUERIDA PARA OBTENER UNA EFICACIA ADECUADA
PE2003000109A 2002-02-01 2003-01-30 Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo PE20040187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/066,091 US7235259B2 (en) 2000-08-03 2002-02-01 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

Publications (1)

Publication Number Publication Date
PE20040187A1 true PE20040187A1 (es) 2004-03-20

Family

ID=27658640

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000109A PE20040187A1 (es) 2002-02-01 2003-01-30 Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Country Status (14)

Country Link
US (1) US7235259B2 (es)
EP (2) EP2305217B1 (es)
JP (1) JP2005523895A (es)
AR (1) AR038375A1 (es)
BR (1) BR0307277A (es)
CA (1) CA2474447A1 (es)
GT (1) GT200300021A (es)
MX (1) MXPA04006650A (es)
PA (1) PA8564901A1 (es)
PE (1) PE20040187A1 (es)
SV (1) SV2004001473A (es)
TW (1) TW200307565A (es)
UY (1) UY27639A1 (es)
WO (1) WO2003063832A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MXPA04007433A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
RU2004123637A (ru) 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040225018A1 (en) * 2003-03-17 2004-11-11 Japan Tobacco Inc. Pharmaceutical compositions of CETP inhibitors
ZA200508159B (en) * 2003-03-17 2007-03-28 Japan Tobacco Inc Pharmaceutical compositions of CETP inhibitors
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1696887A1 (en) * 2003-11-14 2006-09-06 Pfizer Products Inc. Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
KR20060109481A (ko) * 2003-12-04 2006-10-20 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
EP1689368B1 (en) * 2003-12-04 2016-09-28 Bend Research, Inc Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions
JP2008501802A (ja) * 2004-06-08 2008-01-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド 医薬組成物
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MX2007007919A (es) 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
WO2007098270A2 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same
AU2007227544B2 (en) 2006-03-16 2012-11-01 Vertex Pharmaceuticals Incorporated Deuterated hepatitis C protease inhibitors
CN101494979A (zh) * 2006-03-20 2009-07-29 沃泰克斯药物股份有限公司 药物组合物
TW200846343A (en) 2007-02-27 2008-12-01 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
CA2679426A1 (en) 2007-02-27 2008-09-04 Luc Farmer Inhibitors of serine proteases
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
EP2436682A1 (en) 2007-08-30 2012-04-04 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
BRPI0818317A8 (pt) * 2007-10-10 2018-12-18 Mallinckrodt Baker Inc composição, métodos de fabricação de excipiente, comprimido farmacêutico e método de fabricação do mesmo
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Inc Forme di dosaggio di apixaban
EP2675434A1 (en) 2011-02-17 2013-12-25 F.Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
MX2014001849A (es) 2011-08-18 2014-10-24 Reddys Lab Ltd Dr Compuestos de amina heterociclicos sustituidos como inhibidores de proteina de transferencia de ester colesterilo (cetp).
WO2013046045A1 (en) 2011-09-27 2013-04-04 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
JP2016503420A (ja) * 2012-11-19 2016-02-04 ドクター レディズ ラボラトリーズ リミテッド Ｃｅｔｐ阻害剤の薬学的組成物
US10016508B2 (en) 2013-06-03 2018-07-10 Shin-Etsu Chemical Co., Ltd. Composition for hot-melt extrusion and method for producing hot-melt extrusion product using same
US20180282527A1 (en) 2017-03-30 2018-10-04 Shin-Etsu Chemical Co., Ltd. Injection molding composition containing hypromellose acetate succinate and method for producing same
US20240277620A1 (en) * 2021-06-09 2024-08-22 Lonza Bend Inc. Mixed solvents for spray drying for preparation of amorphous solid dispersions
DE102021003906B4 (de) 2021-07-30 2023-03-30 Mirco Bienhaus Verfahren und Vorrichtungen zur Herstellung fester oder halbfester Arzneiformen mit einem mehrschichtigen Aufbau

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
EP0299641B1 (en) 1987-07-17 1992-06-10 Dow Corning Corporation A curable composition
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
DK0580860T4 (da) * 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Fremgangsmåde til fremstilling af en fast dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4316537A1 (de) 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
JPH09501186A (ja) 1994-11-12 1997-02-04 株式会社エルジ化学 コレステリルエステル運搬蛋白質阻害ペプチドおよびこれを含む動脈硬化症のための予防および治療剤
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
GB2305665A (en) 1995-09-26 1997-04-16 Merck & Co Inc Selective ß3 agonists for the treatment of diabetes aand obesity
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
AU9297798A (en) * 1997-09-16 1999-04-05 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
AU3285499A (en) 1998-02-13 1999-08-30 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
WO2000018724A1 (en) 1998-09-25 2000-04-06 Monsanto Company (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY
JP2002525350A (ja) 1998-09-25 2002-08-13 モンサント カンパニー コレステロールエステル輸送タンパク質活性阻害に有効な置換されたｎ−脂肪族−ｎ−芳香族第三級ヘテロアルキルアミン
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
CA2350913C (en) 1999-03-08 2007-01-30 The Kitasato Institute Substances wk-5344a and wk-5344b and process for producing the same
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
AU2001233299A1 (en) 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EE200400033A (et) 2001-06-22 2004-06-15 Pfizer Products Inc. Vähelahustuvaid ja/või happetundlikke ravimeid janeutraliseeritud happelisi polümeere sisaldavad farmatseutilised kompositsioonid
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物

Also Published As

Publication number Publication date
US20030186952A1 (en) 2003-10-02
EP2305217B1 (en) 2014-07-30
US7235259B2 (en) 2007-06-26
EP2305217A1 (en) 2011-04-06
UY27639A1 (es) 2003-09-30
WO2003063832A1 (en) 2003-08-07
AR038375A1 (es) 2005-01-12
SV2004001473A (es) 2004-05-07
MXPA04006650A (es) 2004-10-04
EP1469831A1 (en) 2004-10-27
BR0307277A (pt) 2004-10-26
CA2474447A1 (en) 2003-08-07
PA8564901A1 (es) 2003-11-12
JP2005523895A (ja) 2005-08-11
TW200307565A (en) 2003-12-16
GT200300021A (es) 2003-09-04

Similar Documents

Publication Publication Date Title
PE20040187A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR046749A1 (es) Procedimiento de extrusion para formar farmacos multiparticulados quimicamente estables.
ES2730208T3 (es) Sistema de administración de fármacos para su uso en anticoncepción que comprende un núcleo y una cubierta
ES2363725T3 (es) Método para elaborar dispersiones sólidas de midostaurina.
WO2007001451A3 (en) Stabilized hme composition with small drug particles
AR074543A1 (es) Derivados de imidazo[1,2-a]piridin-2-il, agonistas de receptores 1-fosfato de esfingosina(1s1p1), composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes
RU2014111723A (ru) Антиретровирусная комбинация
HRP20110498T1 (hr) Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
EP2851068A3 (en) Composition comprising a nsaid and paracetamol
DE59904879D1 (de) Verfahren zum herstellen fester darreichungsformen mittels schmelzextrusion
ES2188005T3 (es) Derivados de amidas para el tratamiento de enfermedades mediadas por citoquinas.
EA200700340A1 (ru) Мультичастицы
AR062159A1 (es) Compuestos que inhiben el enlace de la proteina smac al inhibidor de proteinas de apoptosis (iap)
PE20030431A1 (es) DERIVADOS QUINUCLIDINAS COMO AGONISTAS DEL RECEPTOR NICOTINICO DE LA ACETILCOLINA TIPO a7
ECSP066524A (es) Sal antagonista de ccr-2
PE20090837A1 (es) Nuevos compuestos quimicos
PE20171342A1 (es) Compuestos y su uso como inhibidores de bace
RU2010139643A (ru) Способ минимизации полиморфизма
AR055321A1 (es) Compuestos de imidazopiridina uso para a fabricacion de un medicamento para el tratamiento o profilaxis de enfermedades o trastornos en los que se requiere un antagonista de una bomba de acido y composicion farmaceutica que lo comprende
JP2008507543A5 (es)
AR071300A1 (es) Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento
CA3114113A1 (en) Pharmaceutical compositions and methods related to otic therapeutic agents
AR055133A1 (es) Inhibidores de la p38- map - quinasa para el uso de los mismos
SI3027602T1 (en) New indole and pyrrole derivatives, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA Abandonment or withdrawal